The AVANT BIO team will participate in several tracks during the #CHIBioprocessingSummit in Boston, MA this week. On Tuesday, August 20th, Jessica Davis will participate in a panel at the Talent in Biopharma Leadership Workshop - an event designed by talent leaders for talent leaders. On Wednesday, August 21st, Peter Lee will be moderating a panel within the BioProcessing Venture, Innovation and Partnering Conference on the topic “Exit Strategies: M&A vs. IPO Debate” Join the AVANT BIO team and 125+ talent colleagues and walk away with new perspectives and ideas to address today's talent acquisition and retention challenges. Register at https://lnkd.in/efsCuv5Z! Use code TALENT20 for a 20% registration discount. #CHIBioprocessingSummit #growthequity #bioprocessing
About us
Early stage and growth equity investments in Life Sciences, TechBio, Healthtech and Diagnostics. There is enormous opportunity in the life sciences, tech bio and healthtech spaces across all investment stages. The next medical breakthroughs will come from combining incredible new technologies with a greater understanding of biology. AVANT BIO LLC was launched to invest in these opportunities and was structured to attract institutional capital interested in these spaces. We have launched a form for founders seeking funding! Give our team advanced visibility on your company here: https://avantbio.typeform.com/submission
- Website
-
http://www.avant.bio
External link for AVANT BIO
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
New York, NY, US
Employees at AVANT BIO
Updates
-
We are thrilled to announce our latest investment. AVANT BIO has participated in PL BioScience GmbH €7.8 million Series A Financing Round along with 3 additional co-investors to their existing investor base. Forward-looking PL BioScience is pioneering sustainable, non-animal derived cell culture media. Their Human Platelet Lysate (HPL) technology is derived from donated blood no longer suitable for transfusion. HPL provides a sustainable and effective alternative to animal-derived cell culture media. This technology is pivotal in driving progress in cell therapy development. In addition to working capital, AVANT BIO will support the PL Bioscience team with decades of cell culture media experience covering key areas including; pricing strategy, supply chain, and global distribution. We are excited to support PL BioScience GmbH in their next phase of growth as they capitalize on the massive increase in global cell culture media demand. Read PL Bioscience's press release here: https://lnkd.in/eWXEje_K Please follow PL BioScience GmbH to keep up with their latest news Visit PL Bioscience to learn more about their technology: https://lnkd.in/d3rMxqg #cellandgenetherapies #growthequity #cellculturemedia
-
Today, we celebrate the incredible advancements and opportunities that arise when cutting-edge technology meets biology. Artificial Intelligence is revolutionizing biotechnology, enabling us to accelerate discoveries, enhance precision, and drive innovation like never before. At AVANT BIO we are proud to invest in pioneering biotechnology tools that leverage AI to solve some of the most pressing challenges in healthcare and life sciences. From predictive analytics to personalized medicine, the fusion of AI and biology is unlocking new frontiers and transforming the future of biotech. Join us in appreciating the transformative power of AI in biotechnology and the endless possibilities it brings to our industry! 🚀🔬 #NationalAIApreciationDay #Biotech #AI #Innovation #Healthcare #LifeSciences #FutureOfBiotech
-
📣 Just released!, our 2024 Market Outlook for #therapeuticenablingtechnologies, #techbio and #healthtech. Download the full report: https://lnkd.in/gcQ5KxZz The report offers a comprehensive look at the state of the industry based on our market analysis, insights only possible through ongoing discussions with global strategics, input from the founders working in the trenches, and meetings held with investors, family offices, and industry KOLs during a full conference schedule year to date. Investors will gain an understanding of influencing factors and key indicators for these critical segments within Life Sciences, and how they are expected to perform through 2024 and beyond. Founders will gain insights to set expectations as they navigate these uncertain times. #growthequity #innovation #bioprocessing #cellandgenetherapies
-
Just released, our 2024 Market Outlook for #therapeuticenablingtechnologies #techbio and #healthtech. The report offers a comprehensive look at the state of the industry based on our ongoing market analysis, insights only possible through ongoing discussions with global strategics, input from the founders working in the trenches, and meetings held with investors, family offices, and industry KOLs during a full conference schedule year to date. Investors will gain an understanding of influencing factors and key indicators for these critical segments within Life Sciences, and how they are expected to perform through 2024 and beyond. Founders will gain insights to set expectations as they navigate these uncertain times.
-
This week Daniella Kranjac, Founding GP, attended NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals National Meeting and participated in an inspiring "Dancing with Venture” fireside chat also joined by Chris Yochim, Director of Business Development: NIIMBL, and John Bagdonas, CEP, FGE, NDEF VP, Business Development: J.P.Morgan. This event was a fantastic opportunity to connect with industry leaders and delve into groundbreaking discussions shaping the future of biomanufacturing. Key highlights from the meeting were: 💡 Innovation in Biomanufacturing: Experts discussed the latest advancements in biomanufacturing technologies and their impact on the industry. 🤝 Collaboration for Growth: Participated in several discussions on the importance of public-private partnerships in accelerating innovation and driving economic growth. At AVANT BIO, we are committed to staying at the forefront of these developments by playing an integral role in the ecosystem and at events like NIIMBL’s National Meeting so we can foster innovation and growth in the life sciences sector. #Biomanufacturing #Innovation #NIIMBL #AVANTBIO #LifeSciences #growthequity
-
We are thrilled to have participated in the Private Equity Insights Switzerland 2024 conference! This event brought together industry leaders and innovators, providing invaluable insights and networking opportunities. Here are some topics from the event: 🔹 Future of Private Equity: Discussions on emerging trends and investment strategies shaping the industry. 🔹 Sustainable Investing: Insights on integrating ESG factors and driving positive impact through investments. 🔹 Technology and Innovation: Exploring advancements in healthtech and techbio, and their role in transforming the life sciences sector. 🔹 Women in Private Equity: Celebrating the achievements of women leaders and promoting diversity in the industry. Attending this conference reaffirms our commitment to driving innovation and fostering growth in the life sciences and healthtech sectors. Thank you to the organizers and all the incredible participants for making this a highly productive event! #PrivateEquity #HealthTech #LifeSciences #Innovation #AVANTBIO
-
Our team at AVANT BIO had an incredible experience attending SuperReturn this week! At AVANT BIO, we believe in the power of collaboration and innovation to drive the future of life sciences, healthtech, and techbio. Attending SuperReturn provided us with invaluable insights into the latest industry trends, opportunities to connect with fellow leaders, and the chance to showcase our commitment to supporting groundbreaking ventures. Networking with some of the brightest minds in the investment community reaffirmed our mission to empower and invest in visionary startups shaping healthcare's future. We're excited to leverage these new connections and knowledge to continue making a positive impact. #SuperReturn #LifeSciences #Healthtech #TechBio #Innovation #Investment #AVANTBIO #Grothequity #Emergingmanagers
-
We are thrilled to share that AVANT BIO's Founding GP, Daniella Kranjac, recently took the stage at Bridge Funding Global's Bridge Conference in San Francisco, CA. At AVANT BIO, we are proud to be a woman-led emerging firm and share Bridge Funding Global’s commitment to fostering opportunities for high-performing, diverse emerging managers. Daniella's presentation underscored our mission to drive innovation and inclusivity. Discover more about AVANT BIO's work and opportunities to partner with us in shaping the future of life sciences by visiting our website here: https://lnkd.in/e4XSDq6w A heartfelt thank you to Bridge Funding Global for championing diversity and inclusion #AVANTBIO #BridgeTheGap #WomenInBiotech #DiversityInFunding #Innovation #Biotechnology
-
We’re excited to announce Daniella Kranjac, Founding GP has been named an INNOVATE100 honoree in the inaugural Innovation Celebration hosted by Innovation+ and the New Jersey Business & Industry Association (NJBIA), on May 14 at the New Brunswick PAC. Daniella has a long history of supporting innovation in the NJ Life Science sector beginning when she co-founded NJ-based Wave Biotech, LLC while completing her senior year at Stevens Institute of Technology. More information on the event can be found here: https://lnkd.in/eRfJSyh Thanks to James Barrood and NJBIA for supporting the NJ innovation ecosystem! #innovate100 #innovation #leadership #collaboration #innovatenewjersey